Imagin Medical Inc. reported that the final design of the i/Blue Imaging System™ is on target to be demonstrated at the American Urology Association (AUA) Annual Meeting in September. The AUA Annual Meeting, in its 116th year, is the gathering of urologists in the world, providing education as well as access to research, new guidelines and the latest advances in urologic medicine for urologists and urologic health care professionals worldwide. Anticipating the ideal opportunity to address its target market at the meeting, Imagin has scheduled private meetings with leading urologists to demonstrate the advanced capabilities of the i/Blue Imaging System in visualizing bladder cancer. They will be exposed to the potential impact it can have on their patients with bladder cancer. The product will showcase performance against competing visualization products. This product design incorporates feedback from preliminary meetings with the FDA and improvements made to the design for manufacturing that will lead to the preproduction phase. Critical verification requirements established through benchmark testing of competitive systems have been met. Additional testing and specification development have been focused on contrast-agent-induced fluorescence and the ability to replicate clinical observations in a bench-level study. Sensitivity of the system can now be fully demonstrated with the test methods that have been established.